Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia.

Johansson P.

Semin Thromb Hemost. 2006 Apr;32(3):171-3. Review.

PMID:
16673273
2.

Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe.

Griesshammer M, Struve S, Harrison CM.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):422-9. Review.

PMID:
16810618
3.
4.

Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.

Elliott MA, Tefferi A.

Curr Hematol Rep. 2004 Sep;3(5):344-51. Review.

PMID:
15341701
5.

Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia.

Murphy S.

Semin Hematol. 1999 Jan;36(1 Suppl 2):9-13. Review.

PMID:
9930551
6.

Clinical predictors of outcome in MPN.

Passamonti F, Maffioli M, Merli M, Ferrario A, Caramazza D.

Hematol Oncol Clin North Am. 2012 Oct;26(5):1101-16. doi: 10.1016/j.hoc.2012.07.009. Epub 2012 Aug 28. Review.

PMID:
23009940
7.

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.

Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.

Semin Thromb Hemost. 2006 Apr;32(3):174-207. Review.

PMID:
16673274
8.

Risk-adapted therapy in essential thrombocythemia and polycythemia vera.

Finazzi G, Barbui T.

Blood Rev. 2005 Sep;19(5):243-52. Review.

PMID:
15963833
9.

How common are myeloproliferative neoplasms? A systematic review and meta-analysis.

Titmarsh GJ, Duncombe AS, McMullin MF, O'Rorke M, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M, Anderson LA.

Am J Hematol. 2014 Jun;89(6):581-7. Review. Erratum in: Am J Hematol. 2015 Sep;90(9):850.

PMID:
24971434
10.
11.
12.
13.

Historical perspective on the treatment of essential thrombocythemia and polycythemia vera.

Gilbert HS.

Semin Hematol. 1999 Jan;36(1 Suppl 2):19-22. Review.

PMID:
9930553
14.

Polycythaemia vera and essential thrombocythaemia: current treatment strategies.

Penninga EI, Bjerrum OW.

Drugs. 2006;66(17):2173-87. Review.

PMID:
17137402
15.

Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.

Barbui T, Finazzi G.

Semin Thromb Hemost. 2007 Jun;33(4):321-9. Review.

PMID:
17525889
16.
17.

Influence of the assays of endogenous colony formation and serum erythropoietin on the diagnosis of polycythemia vera and essential thrombocythemia.

Mossuz P; Groupe d'Etudes Multicentriques des Syndrome MyéloProlifératifs (GEMSMP).

Semin Thromb Hemost. 2006 Apr;32(3):246-50. Review.

PMID:
16673278
18.
19.
20.

Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.

Falanga A, Marchetti M, Barbui T, Smith CW.

Semin Hematol. 2005 Oct;42(4):239-47. Review.

PMID:
16210037

Supplemental Content

Support Center